PSA Screening-Good News on Treating Advanced Prostate Cancer
Last weeks American Society of Clinical Oncology (ASCO) meetings in Chicago reported some good news on the advanced prostate cancer treatment front. By adding radiation treatment to hormone therapy, doctors were able to extend the life of men with advanced prostate cancer. Seventy four percent of men who received radiation therapy along with hormone therapy were alive after seven years, compared with 66% of those who received hormone therapy alone. Importantly, only 10% of those who received radiotherapy died from prostate cancer itself, compared with 26% of those who received only hormone therapy. Talk to your doctor about this new treatment option-the results are exciting!
Another interesting and important development released at the meetings are the new rules to help patients gain access to investigational drugs (these include the new drugs being tested to treat cancer). It is intended to improve access to investigational drugs for patients with serious or immediately life-threatening diseases or conditions who lack other therapeutic options and who may benefit from such therapies.
“Expanded Access to Investigational Drugs for Treatment Use,”amends regulations on expanded access to investigational new drugs for treating patients. The final rule clarifies existing regulations and adds new types of expanded access for treatment use. Under the final rule, expanded access to investigational drugs for treatment use will be available to:
- individual patients, including in emergencies
- intermediate-size patient populations
- larger populations under a treatment protocol or treatment investigational new drug application (IND)
A new website has been created by ASCO and the FDA to make investigational drugs more accessible to patients. The site provides tools to help doctors and patients navigate through the complex expanded access program. The website is, http://university.asco.org. Talk to your doctor about this helpful resource!